{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:15:09Z","timestamp":1779916509172,"version":"3.53.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op Tegen Kanker","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antibodies blocking programmed cell death 1 (PD-1) have encouraging responses in patients with metastatic melanoma. Response to anti-PD-1 treatment requires pre-existing CD8+ T cells that are negatively regulated by PD-1-mediated adaptive immune resistance. Unfortunately, less than half of melanoma tumours have these characteristics. Combining anti-PD-1 treatment with other immunomodulating treatments to activate CD8+ T cells is therefore of vital importance to increase response rates and long-term survival benefit in melanoma patients. Both preclinical and retrospective clinical data support the hypothesis that radiotherapy increases the response rates to anti-PD-1 treatment by stimulating the accumulation and activation of CD8+ T cells in the tumour microenvironment. Combining radiotherapy with a PD-1 blocking antibody might therefore increase response rates and even induce long-term survival. The current phase II study will be testing these hypotheses and aims to improve local and distant tumour responses by exploiting the pro-immunogenic effects of radiotherapy in addition to anti-PD-1 treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The trial will be conducted in patients with metastatic melanoma. Nivolumab or pembrolizumab, both antibodies that target PD-1, will be administrated according to the recommended dosing schedule. Prior to the 2nd cycle, radiotherapy will be delivered in three fractions of 8\u00a0Gy to the largest FDG-avid metastatic lesion. The primary endpoint is the proportion of patients with a partial or complete response in non-irradiated metastases according to RECIST v1.1. Secondary endpoints include response rate according to immune related response criteria, metabolic response, local control and survival. To identify peripheral blood biomarkers, peripheral blood mononuclear cells and serum samples will be collected prospectively before, during and after treatment and subjected to flow cytometry and cytokine measurement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The current phase II trial aims at exploring the suggested benefits of combining anti-PD-1 treatment and radiotherapy. The translational focus on immunologic markers might be suitable for predicting efficacy and monitoring the effect so to improve patient selection for future clinical applications.<\/jats:p>\n                <jats:p><jats:italic>ClinicalTrials.gov Identifier<\/jats:italic> NCT02821182<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-017-1123-x","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T02:47:34Z","timestamp":1485830854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response"],"prefix":"10.1186","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02821182","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katrien","family":"De Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Sundahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"van Gele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Chevolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Brochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"issue":"7","key":"1123_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1634\/theoncologist.2009-0237","volume":"15","author":"C Kim","year":"2010","unstructured":"Kim C, Lee CW, Kovacic L, et al. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. Oncologist. 2010;15(7):765\u201371.","journal-title":"Oncologist"},{"issue":"Suppl 5","key":"1123_CR2","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126\u201332.","journal-title":"Ann Oncol"},{"issue":"26","key":"1123_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"10","key":"1123_CR4","doi-asserted-by":"publisher","first-page":"e1042198","DOI":"10.1080\/2162402X.2015.1042198","volume":"4","author":"K De Wolf","year":"2015","unstructured":"De Wolf K, Vermaelen K, De Meerleer G, et al. The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology. 2015;4(10):e1042198.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1123_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","volume":"83","author":"D Schaue","year":"2012","unstructured":"Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"1123_CR6","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379\u201388.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1123_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687\u201395.","journal-title":"J Clin Investig"},{"issue":"4","key":"1123_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1123_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1123_CR10","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ijc.28558","volume":"134","author":"SA Gerber","year":"2014","unstructured":"Gerber SA, Lim JY, Connolly KA, et al. Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer. 2014;134(10):2383\u201392.","journal-title":"Int J Cancer"},{"issue":"3","key":"1123_CR11","doi-asserted-by":"publisher","first-page":"e982382","DOI":"10.4161\/2162402X.2014.982382","volume":"4","author":"I Chevolet","year":"2015","unstructured":"Chevolet I, Speeckaert R, Schreuer M, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology. 2015;4(3):e982382.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1123_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cct.2010.07.008","volume":"31","author":"AP Mander","year":"2010","unstructured":"Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials. 2010;31(6):572\u20138.","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"1123_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"23","key":"1123_CR14","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1123_CR15","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773\u201382.","journal-title":"Eur J Cancer"},{"key":"1123_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-014-0376-x","volume":"13","author":"I Chevolet","year":"2015","unstructured":"Chevolet I, Speeckaert R, Schreuer M, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9.","journal-title":"J Transl Med"},{"issue":"5","key":"1123_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.13100","volume":"171","author":"I Chevolet","year":"2014","unstructured":"Chevolet I, Speeckaert R, Haspeslagh M, et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol. 2014;171(5):987\u201395.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1123_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-017-1123-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-017-1123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:39:54Z","timestamp":1628613594000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-017-1123-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1186\/s12967-017-1123-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]},"assertion":[{"value":"6 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"21"}}